NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.
Publication
, Journal Article
von Mehren, M; Kane, JM; Riedel, RF; Sicklick, JK; Pollack, SM; Agulnik, M; Bui, MM; Carr-Ascher, J; Choy, E; Connelly, M; Dry, S; Ganjoo, KN ...
Published in: J Natl Compr Canc Netw
November 2022
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2022
Volume
20
Issue
11
Start / End Page
1204 / 1214
Location
United States
Related Subject Headings
- Receptor, Platelet-Derived Growth Factor alpha
- Proto-Oncogene Proteins c-kit
- Oncology & Carcinogenesis
- Mutation
- Humans
- Gastrointestinal Stromal Tumors
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
von Mehren, M., Kane, J. M., Riedel, R. F., Sicklick, J. K., Pollack, S. M., Agulnik, M., … Hang, L. E. (2022). NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw, 20(11), 1204–1214. https://doi.org/10.6004/jnccn.2022.0058
Mehren, Margaret von, John M. Kane, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, et al. “NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.” J Natl Compr Canc Netw 20, no. 11 (November 2022): 1204–14. https://doi.org/10.6004/jnccn.2022.0058.
von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, et al. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw. 2022 Nov;20(11):1204–14.
von Mehren, Margaret, et al. “NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.” J Natl Compr Canc Netw, vol. 20, no. 11, Nov. 2022, pp. 1204–14. Pubmed, doi:10.6004/jnccn.2022.0058.
von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Poppe M, Schuetze S, Shabason J, Spraker MB, Zimel M, Bergman MA, Sundar H, Hang LE. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw. 2022 Nov;20(11):1204–1214.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2022
Volume
20
Issue
11
Start / End Page
1204 / 1214
Location
United States
Related Subject Headings
- Receptor, Platelet-Derived Growth Factor alpha
- Proto-Oncogene Proteins c-kit
- Oncology & Carcinogenesis
- Mutation
- Humans
- Gastrointestinal Stromal Tumors
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis